Sensory testing and topical capsaicin can characterize patients with rheumatoid arthritis

Bjoern Anders1 · Malte Anders1 · Matthias Kreuzer2 · Sebastian Zinn3 · Lukas Fricker1 · Christoph Maier4 · Miriam Wolters1 · Michaela Köhm1,5 · Frank Behrens1,5 · Carmen Walter1

Received: 8 October 2021 / Revised: 13 April 2022 / Accepted: 19 April 2022 / Published online: 30 April 2022 © The Author(s) 2022

Abstract

Background and objectives Our study aimed at examining the long-time inflammatory effects of rheumatoid arthritis (RA) as chronic immune-mediated disease on pain sensation and neuropathy development compared to healthy subjects (HS).

Methods We used the quantitative sensory testing (QST) protocol of the German Research Network on Neuropathic Pain and Electroencephalography (EEG)–based contact heat evoked potentials (CHEPs) before and after topical capsaicin application. We recruited 16 RA patients in remission or low disease activity state (mean age: 59.38 years [± 10.18]) and 16 healthy subjects (mean age: 56.69 years [± 8.92]).

Results The application of capsaicin cream on the thigh provoked a stronger effect in HS for both mechanical and heat pain thresholds (MPT and HPT, resp.), according to the area under the receiver operation characteristic (AUROC) (HS: HPT: 0.8965, MPT: 0.7402; RA: HPT: 0.7012, MPT: 0.6113). We observed contrary effects regarding changes in CHEPs (HS: $g^{max} = -0.65$; RA patients: $g^{max} = 0.72$).

Conclusion As the overall effect of topical capsaicin application was higher in HS for QST, we suggest the existence of a sensitization of TRPV1 channels in RA patients caused by long-time chronic inflammation, despite a lack of clinical signs of inflammation due to adequate treatment. The effect in CHEPs probably uncovers neuropathic symptoms. The effect of topical capsaicin on HPTs and CHEPs can show the long-term consequences of RA patients in remission.

Key Points

• The effect of topical capsaicin may represent the extent of TRPV1 sensitization in rheumatoid arthritis.
• The effect of topical capsaicin on the amplitude level of CHEPs can unmask neuropathic symptoms.
• The effect of topical capsaicin on CHEPs and HPTs can show the long-term consequences and the treatment success of RA patients in remission.

Keywords Capsaicin · CHEPs · Rheumatoid arthritis
Introduction

Rheumatoid arthritis (RA) is an immune-mediated joint disease that can severely reduce function and quality of life. RA patients report pain as one of the most important factors for those negative effects [1], which serves as a substitute marker for impairment and is often associated with disease activity [2]. Nevertheless, RA patients show disease-associated pain problems even in the absence of inflammatory signs or low disease activity scores [3]. Disease-modifying antirheumatic drugs (DMARDs) usually represent the basic treatment for RA, while nonsteroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids (GCs) are used for symptomatic treatment [4, 5]. Further options in case the basic therapy is insufficient are topical capsaicin, weak opioids, and treatments such as joint infiltrations or surgical management. However, a significant number of patients continue to experience pain despite adapted treatment [6]. Recent survey-based research emphasized that certain groups of RA patients even suffer from a neuropathic pain component, which would require treatment adjustment according to different treatment strategies than immunosuppressive drugs [7].

One method to detect sensory disorders and neuropathic pain is quantitative sensory testing (QST), which can provide valuable information about the underlying pathophysiological mechanisms of pain [8, 9]. Moreover, QST may allow predictions and reflections of treatment responses [10]. In previous studies with RA patients, only single elements of QST have been applied; e.g., the RA disease resulted in higher baseline pain levels in those patients who reported lower pressure pain thresholds (PPTs) [11]. While QST is a well-researched method for the detection and characterization of sensory disorders, it is fully dependent on the subjective input from the participants. Hence, recent research also focused on electroencephalography (EEG)–based contact heat evoked potentials (CHEPs), which is an established objective procedure to assess the function of the Aδ and C fibers [12]. It relies on EEG data, which is not dependent on the subjective clinical examination as compared to QST [13]. The readout as extracted from the EEG can serve as an indirect marker of the function of the nociceptive system [14, 15]. One possible use is the evaluation of the effects of analgesics on the objective response in the EEG after standardized noxious stimulation [16].

With our study, we intend to characterize the pain profile of well-treated RA patients using QST and CHEPs. To our knowledge, CHEPs have not been used to study the pain profile of patients with RA. We further analyze the sensitizing effects of topically applied capsaicin on QST and CHEPS recordings. We aim at identifying parameters to track the treatment response of RA patients and quantify the neuropathy development which may be caused by chronic inflammation and pain. We further aim at determining if either QST, CHEPs, or both are a suitable method to develop approaches for the stratified treatment of pain in RA patients.

Materials and methods

Study population

We included 16 patients (see Table 1) with a diagnosis of rheumatoid arthritis with low disease activity or in remission according to DAS28 < 3.2 (RA group, 8 male and 8 female, mean age: 59.38 years [± 10.18], PainDETECT score: 6.75 [± 5.57]) and 16 healthy subjects (HS group, 8 male and 8 female, mean age: 56.68 years [± 8.93]). Both groups were asked to refrain from taking pain medication of any kind for 5 days prior to the study visit. We excluded patients with a PainDETECT score over 18 [17], who currently abused alcohol or drugs (evaluated via verbal anamnesis), who took antidepressants, or who suffered from any other chronic pain or diagnosed neuropathic diseases. All subjects had a BMI < 30 kg/m² and were of Caucasian ethnicity.

Table 1 Characteristics of subjects

| Characteristics                  | HS % or mean [SD] | RA % or mean [SD] |
|---------------------------------|------------------|------------------|
| Age                             | 56.69 years ± 8.92 | 59.38 years ± 10.18 |
| Male/Female                     | 50%/50%          | 50%/50%          |
| Caucasian                       | 100%             | 100%             |
| BMI [kg/m²]                     | 23.7 ± 3.67      | 25.12 ± 3.42     |
| PainDETECT score                | 6.75 ± 5.57      |                  |
| Treatment                       |                  |                  |
| No specific treatment           | 12.50%           |                  |
| MTX only                        | 12.50%           |                  |
| TNF-inhibitor only              | 25.00%           |                  |
| MTX + TNF-inhibitor             | 43.75%           |                  |
| JAK-inhibitor                   | 6.25%            |                  |
| Disease duration                |                  |                  |
| 1–3 years                       | 6.25%            |                  |
| 3–5 years                       | 12.50%           |                  |
| 5–10 years                      | 56.25%           |                  |
| 10+ years                       | 25.00%           |                  |
| CRP [mg/l]                      | 3.26 ± 3.58      |                  |
| SJC28 (swollen joint count)     | 0.31 ± 0.68      |                  |
| TJC28 (tender joint count)      | 0.75 ± 1.35      |                  |
| DAS28 (CRP-3)                   | 1.68 ± 0.83      |                  |
Patients were only included if their RA treatments were unchanged for at least 3 months prior to the study, due to a stable disease state (remission or low disease activity with a DAS28 < 3.2). The subjects had to confirm to be mentally and physically able to manage the study procedure of about 4 h. We recruited the patients in the RA group from the Division of Rheumatology of the University Hospital of Frankfurt am Main (Germany). Both HS and RA groups underwent a training visit for about 30 min to assure they could consistently evaluate and tolerate both QST and CHEPs procedures.

**QST**

QST is a standardized protocol of the German Research Network on Neuropathic Pain (DFNS) using well-established tests for nearly all aspects of somatosensation by thermal and mechanical testing procedures. It consists of seven tests measuring 13 parameters [9, 18].

We performed three sets of QST measurements on the dominant body side: the first on the front of the thigh and the second on the back of the hand. Before the third measurement, we applied 200 mg of capsaicin cream (concentration: 0.2%) with an exposure time of 20 min and then measured a full set of QST on the front of the same thigh as in set one.

**Thermal detection and thermal pain thresholds**

The subject’s thermal sensation was determined using a TSA 2001-II (MEDOC, Israel) thermal sensory testing device. We determined the cold detection threshold (CDT) and warm detection threshold (WDT) by asking the subject to press a trigger button if they experienced any cold or warm sensation. The number of paradoxical heat sensations (PHS) was determined during the thermal sensory limen procedure (TSL; the difference limen for alternating cold and warm stimuli). The subjects had to press the trigger if they experienced any cold or warm sensation. Afterwards, we asked them to describe the sensation as cold or warm. We determined the cold pain threshold (CPT) and heat pain threshold (HPT) by asking the subjects to press the trigger if they experienced a painful component in addition to sensation of cold or heat. The mean threshold temperature of three consecutive measurements was calculated. Cutoff temperatures were 0 and 50 °C. We set the baseline temperature to 32 °C (center of neutral range) and the rectangular contact area of the thermode was 7.84 cm² [9, 18].

**Mechanical detection threshold (MDT)**

We measured the mechanical detection threshold (MDT) to assess the Aβ fiber function with a standardized set of von Frey filaments (Marstock, Germany) of forces between 0.25 and 256 mN. The contact area was of uniform size and shape (round, 0.5 mm diameter). The mean of five series defined the threshold of ascending and descending stimulus intensities [9, 18].

**Mechanical pain threshold (MPT)**

The mechanical pain threshold (MPT) was determined to assess the Aδ fiber function with respect to mechanical allodynia. We used a set of PinPrick stimulators (MRC Systems, Germany) with a flat contact area with a diameter of 0.25 mm and forces between 8 and 512 mN. The threshold was calculated as the geometric mean of five series of ascending and descending stimulus intensities [9, 18].

**Mechanical pain sensitivity (MPS)/dynamic mechanical allodynia (DMA)**

Using PinPricks, we further tested mechanical pain sensitivity (MPS). To obtain a stimulus–response function, seven pinprick stimuli were applied in a balanced order with five repetitions for each PinPrick. We asked the subjects to give pain ratings for each stimulus on a 0–100 numerical rating scale (NRS) for 0 = no pain and 100 = most intense pain imaginable. Applying single strokes of a set of three light tactile stimulators (a cotton wisp, a cotton wool tip, and a standardized brush; five times each) of approximately 1–2 cm in length over the skin, we determined stimulus–response functions for dynamic mechanical allodynia (DMA). Subjects also rated pinprick stimuli on hand/thigh with a 0–100 NRS for each stimulus [9, 18].

**Wind-up ratio (WUR)**

At first, subjects rated a single 256 mN PinPrick stimulus. Afterwards, we applied a series of 10 stimuli with a frequency of 1/s. The subjects rated pain intensity on a scale from 1 to 100 after we applied all 10 stimuli. The procedure was repeated five times [9, 18].

**Vibration detection threshold (VDT)**

A Rydel–Seiffer tuning fork (64 Hz, 8/8 scale) placed over a bony prominence of the middle finger joint/knee for three times determined the vibration detection threshold, mediated by Aβ fibers [9, 18].

**Pressure pain threshold (PPT)**

Three sets of slowly increasing stimuli (50 kPa/s) using a pressure gauge device (Jtech Medical, Midvale, USA) with
a probe area of 1 cm² determined the pressure pain threshold (PPT). PPT makes it possible to assess the pain sensitivity of the deep muscles, probably mediated by the muscles Aδ and C fibers [9, 18].

**Topical capsaicin**

We applied 200 mg of capsaicin cream (capsaicin 0.2% incorporated in Basiscreme DAC) to the front of the thigh, followed by an exposure time of 20 min. The QST measurements were performed in this area for a third time and 200 mg of capsaicin cream was applied to the non-dominant forearm area as well, followed by an exposure time of 20 min. We then placed the thermode for CHEP measurements in this area and performed measurements using a stimulation temperature of 54 °C.

**CHEPs**

Each study took place with the subject sitting in a quiet room. We equipped each subject with an EEG cap (Guger Technologies, Austria), which incorporated 21 active EEG electrodes according to the 10–20 system, attached to a g.Tec g.HIamp multichannel amplifier. We measured the location of the Cz electrode, which was placed midway between the nasion (most anterior point of the frontonasal suture) and inion (most prominent point of the occipital bone) and midway between both tragi. We used active EEG electrodes with a very low output impedance to minimize the influence of artifacts from the movement of the electrode cables [19]. We recorded the raw EEG using the g.Recorder software from g.Tec with a sample rate of 512 Hz.

Subjects underwent four series of CHEP stimuli with 48 °C, 51 °C, 54 °C, and 54 °C after topically applied capsaicin at the non-dominant volar forearm. Each series contained seven stimuli of each temperature with the inter stimulus interval set to 40 s. The subjects verbally rated every stimulus on a 0–100 NRS approximately 10 s after its appearance.

**EEG analysis**

For data preprocessing, EEGLAB, a MATLAB-based (The MathWorks Inc., Natick, MA, USA) toolbox, was used [20]. We down-sampled the EEG to 256 Hz and applied a high-pass filter at 1 Hz and a low-pass filter at 42 Hz to eliminate 50 Hz line noise. We re-referenced the datasets to mathematically linked electrodes on the earlobes [21].

We cleaned the EEG data using Artifact Subspace Reconstruction (ASR) with a threshold of 20 standard deviations [22] and then epoched the data from −1 to +2 s around the stimulus onset.

**Statistical analysis**

We carried out the statistical analysis using MATLAB. We logarithmized the QST data of CDT, WDT, PPT, MPT, MPS, DMA, WUR, and MDT and kept the rest of the data in the original format [23].

We confirmed the normal distribution of the QST and NRS₁₀₀ data with the Kolmogorov–Smirnov test. We compared the data using a two-sample $t$ test and calculated the area under the receiver operating characteristics (AUROC) for HPTs, MPTs, and CHEPs-NRS ratings with MATLAB’s toolbox “ROC Curve.” AUROC has been chosen as this method has proven to be able to differentiate between two conditions, i.e., in our case between RA patients and HS [24].

We calculated the $p$ values for CHEPs using the Mann–Whitney $U$ test and corrected the obtained $p$ values for multiple comparisons with Bonferroni correction. The significance level was set to $p < 0.05$. Furthermore, we calculated Hedges’ $g$ effect size [25] at every data point. As a rule of the thumb, absolute effect sizes above 0.5 present a “medium” effect [26]. Hence, we only considered $g^* > |0.5|$ as relevant.

**Results**

**Comparison of QST values of RA patients versus healthy subjects (see Table 2)**

We observed only significant differences for PPT values on the hand ($p = 0.0264$). While HPTs (as also all other parameters were within the normal range) on the hand ($p = 0.8912$) and on the thigh ($p = 0.2595$) did not yield a significant difference, the application of capsaicin cream on the thigh led to a significant difference between both groups for WDTs ($p = 0.0282$) and HPTs ($p = 0.0277$). We compared the effect of capsaicin in both groups on the HPTs (see Fig. 1; HS: $p < 0.0001$; RA: $p = 0.0316$) and on the MPTs (see Fig. 2; HS: $p = 0.0186$; RA: $p = 0.2136$) between before and after the application.

**AUROC analysis of HPT values**

Due to the incoherent effect of capsaicin cream on the HPT and MPT, we also calculated AUROC (see Table 3). Those values demonstrated a more robust separation effect in HS (HPT: 0.88, MPT: 0.70) compared to RA patients (HPT: 0.73, MPT: 0.63) before and after the application of capsaicin cream.
CHEPs

We did not observe any significant differences or effect sizes above 0.5 or below −0.5 for the temperatures of 48 °C and 51 °C respectively between both groups. Hence, we only plotted the CHEPs for 54 °C stimulation temperature in Fig. 2. Regarding the magnitude of the n-amplitude at 54 °C stimulation temperature, HS and RA patients showed a significant difference with a maximum effect size of $g^{*}_{max} = −0.95$ at 469 ms. After the application of capsaicin cream, HS experienced an effect with a negative $g^{*}_{max} = −0.65$ at 535 ms and RA patients with a positive $g^{*}_{max} = 0.72$ at 473 ms. We observed no significant difference comparing both groups after the application of capsaicin cream (see Fig. 2). NRS ratings (see Table 4) did not yield differences before and after capsaicin application and the AUROC analysis did not show any relevant separation (HS: AUROC = 0.57, $p = 0.1646$; RA patients: AUROC = 0.50, $p = 0.4486$).

Discussion

This study provides an extensive QST data set combined with measurements of CHEPs in RA patients in remission or low disease activity and a control group of healthy subjects.
PPT measurements on the hand yielded a significant difference between RA and HS, which corresponds to the results of previous studies [11, 27]. However, in contrast to past studies, the included RA patients did not declare lower HPTs [28]. Comparing the AUROC values for the difference in HPT values after the application of capsaicin cream underlines a stronger separation in HS (AUROC ~ 0.90, p < 0.0001) vs RA patients (AUROC ~ 0.70, p ~ 0.03), underlining possibly a more crucial impact of the compound in HS. The underlying mechanisms for these observations are not yet clear. We assume an overexpression or sensitization of TRPV1 receptors in RA patients [29]. Regarding our results, HS experience a stronger sensitization effect than RA patients after the application of capsaicin cream for both HPTs and MPTs, according to the AUROC values.

Although the capsaicin-induced area of hyperalgesia is larger in RA patients with active disease [30], potentially caused by overexpressed or sensitized TRPV1 receptors, we observed a clearer separation effect for the MPT change in RA patients.
HS (AUROC ~ 0.74, p ~ 0.02) than in RA (AUROC ~ 0.61, p ~ 0.21) after the application of capsaicin cream. This overexpression is shown in more recent research [29]. The study did not report any NRS ratings in addition to the area of hyperalgesia on that we were able to show a clearer effect in HS.

Other agonists for TRPV1 besides capsaicin are endogenous components like substance P and calcitonin gene–related peptide, two of the main neuropeptides involved in the development of inflammation. Both peptides increase the TRPV1 expression in RA synoviocytes [29]. TRPV1 deletion may block the pro-inflammatory function, thereby reducing synovial inflammation. Among other procedures, deletion of gene segments responsible for the expression of TRPV1 prevented the progression of RA and the establishment of hyperalgesia priming. This resulted in overall decreased disease activity and pain sensation during the chronic phase of RA. TRPV1-deficient mice with experimental RA showed decreased synovial inflammation, bone erosion, and cartilage damage in the joint in the early disease phase [31]. The expression of TRPV1 increased after inflammation whereas TRPV1 deletion inhibited synovial macrophages [31]. Different changes in the expression of TRPV1 are described. In inflammation models, there is an increase in TRPV1 expression at the RNA and protein level, whereas in models of neuropathic pain there is sometimes a reduction [32].

In our study, for both MPTs and HPTs, the sensitization effect of topical capsaicin is weaker in RA patients, compared to HS. This observation might rather result from sensitization processes due to RA-related inflammation than from difficulties to sensitize TRPV1 channels in RA patients, even in the absence of clinical inflammation signs. This context might reduce the potential for a sensitization effect of topical capsaicin to the same extent as in HS. The influence of inflammatory mediators on TRPV1 and nociception may also be different. Both pronociceptive and antinociceptive influences can be mediated by modification at TRPV1 [32].

Excessive activation of the TRPV1 channel, possibly through permanent activation by the inflammatory soup as nociceptive input with the associated Ca2+ influx, ultimately leads to desensitization of the nociceptor and the associated reduced pain sensitivity. It also means a loss of function, which may be irreversible [33]. This could contribute to the development of a neuropathic pain type with mechanical pain threshold changes [34]. The observed changes in PPT for deep mechanical pain in RA patients show such a difference compared to healthy subjects.

Previous studies utilized QST to identify subgroups of neuropathic pain with different etiologies and classify treatment responders [35]. Due to our small sample size, we did not perform a subgroup analysis. This study, however, shows that this is a possible approach for RA patients. Larger study populations might yield similar clusters, with topically applied capsaicin as a supplementary measure. A recent publication analyzed the relationship between RA, COVID-19, and the immune-neuroendocrine system and concludes that RA patients have an altered response of the immune-neuroendocrine system [36]. However, our data does not support any further conclusions regarding a possible effect of capsaicin on the immune-neuroendocrine system.

For CHEPs, regarding the maximum amplitudes, other studies showed a latency-shortening effect of topical capsaicin in healthy subjects [37]. We further revealed a maximum amplitude change for the n-wave after capsaicin application in RA patients to ~8.77 μV, whereas before the n-wave was unclear to detect. This change was almost undetectable in HS (~8.77 to ~9.51 μV).

Our CHEP results suggest that pain that is assessed in RA patients in remission state can be characterized as neuropathic symptom with need for a different treatment strategy than change or intensification of immune-suppressive therapy. Comparing the event-related potentials (ERPs) of 54 °C stimuli between HS and RA patients, RA has a strong negative effect on the height of the n-amplitude (gmax = −0.95), which corresponds to past research for neuropathic patients [38–40]. The application of capsaicin cream causes a positive impact on the height of the

| Table 3 | AUROC analysis of HTPs and MPTs (thigh) before and after the application of capsaicin cream |
|-----------------|------------------------------------------|
| Compared values | AUROC value | Sensitivity | Specificity |
| HPTs HS vs RA patients | 0.61 | 0.69 | 0.63 |
| HPTs after capsaicin application HS vs RA patients | 0.76 | 0.75 | 0.81 |
| HPTs before vs after capsaicin application in HS | 0.90 | 0.81 | 0.88 |
| HPTs before vs after capsaicin application in RA patients | 0.70 | 0.69 | 0.69 |
| MPTs HS vs RA patients | 0.67 | 0.69 | 0.69 |
| MPTs after capsaicin application HS vs RA patients | 0.59 | 0.81 | 0.50 |
| MPTs before vs after capsaicin application in HS | 0.74 | 0.75 | 0.69 |
| MPTs before vs after capsaicin application in RA patients | 0.61 | 0.69 | 0.56 |

Relevant separations are shown in bold.
n-amplitude in RA patients ($g_{max}^* = 0.72$). The negative impact in HS ($g_{max}^* = -0.65$) could be deceiving, as it is most likely a shortened latency, and the maximum amplitude hardly changes. This effect corresponds to past research as well, where a latency-shortening effect of topical capsaicin in healthy subjects has already been shown [37]. After application of the capsaicin cream, no significant area of distinction can be shown between both groups, as the topical capsaicin could mask neuropathies of RA patients by sensitization. Interestingly, we cannot observe a similar sensitization effect on the n-amplitude in HS. For this, we propose that CHEP amplitudes at some point reached a kind of maximum, which was already triggered at $54 \, ^\circ C$ in HS. In RA patients, due to neuropathic symptoms, this is only possible through further sensitization, whereby no significant differentiation is possible after the application of capsaicin cream between both groups.

### Conclusion

We conclude that carrying out either QST or CHEPs alone might not be sufficient to show a possible (peripheral/central) pain sensitization of RA patients in remission to pain stimuli or any neuropathic component. We were able to show a diverging reaction to the capsaicin cream between those groups using both these methods. Our results are applicable to RA patients in remission or low disease activity with a stable treatment and a maximum NRS$_{10}$ rating of RA pain of 3/10 before the study sessions. Thus, with the study setup described in this paper, TRPV1 sensitization and neuropathy development regarding the effect of capsaicin cream on their HPTs/MPTs and ERP images can be evaluated by comparing RA patients with a HS group.

Topical capsaicin application can be utilized to evaluate a possible neuropathy or sensitization/overexpression of TRPV1 channels in RA patients or similar inflammatory diseases. Applying CHEPs or HPT before and after capsaicin application, both methods were sufficient to show representative diverging effects already in a small study population. The comparison of different RA treatment approaches or disease durations and their effect on the described reaction to topical capsaicin is a possible application of these methods in future research. Combining QST and CHEPs before and after the application of topical capsaicin is thus advisable for study setups that compare inflammatory diseases with healthy control groups. The change in TRPV1 expression or the extent of a neuropathy development may show the ability of medications to suppress chronic inflammation and pain. The effect of topical capsaicin on HPTs or CHEPs might outline insufficient treatments of chronic inflammations in RA or the need for an additional treatment of neuropathic symptoms. Future studies need to prove if treatment changes

| Table 4 | NRS ratings following the $54 \, ^\circ C$ stimulus before and after the application of capsaicin cream. We show the 95% CI for the difference between means of HS and RA. |
|------------------|------------------|------------------|------------------|
| NRS (0–100) ratings | HS | RA patients |
| Mean [NRS$_{10}$] | SD | 95% CI (HS-RA) | AUCROC | Mean [NRS$_{10}$] | SD | 95% CI (HS-RA) | AUCROC |
| $54 \, ^\circ C$ | 27.85 | 22.64 | 0.1646 | 0.57 | $54 \, ^\circ C$ | 26.48 | 21.81 | 0.4486 | 0.50 |
| + Caps | 23.85 | 22.11 | 0.0846 | 1.00 | + Caps | 21.98 | 20.98 | 0.2946 | 0.50 |
can prevent or reduce the physiological effects of RA that are described in this manuscript.

**Funding** Open Access funding enabled and organized by Projekt DEAL. This research was funded by the budget of the Group for Early Clinical Development and Human Pain Models, Fraunhofer ITMP. This research was supported by the research funding program Landes-Offensive Zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz (LOEWE) of the State of Hessen, Research Center for Translational Medicine and Pharmacology (TMP). BA was supported by the EKFS Offensive Zur Entwicklung Wissenschaftlichökonomischer Exzellenz (LOEWE) of the State of Hessen, Research Center for Translational Medicine and Pharmacology (TMP). This research was supported by the research funding program Landes-Offensive Zur Entwicklung Wissenschaftlichökonomischer Exzellenz (LOEWE) of the State of Hessen, Research Center for Translational Medicine and Pharmacology (TMP). This research was funded by the budget of the Group for Early Clinical Development and Human Pain Models, Fraunhofer ITMP. This research was supported by the research funding program Landes-Offensive Zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz (LOEWE) of the State of Hessen, Research Center for Translational Medicine and Pharmacology (TMP).

**Declarations**

**Ethics approval** The study has been approved by the ethics committee of Frankfurt am Main and therefore been performed in accordance with the ethical standards laid down in the Declaration of Helsinki and its later amendments. All participants gave their written informed consent prior to their inclusion in the study.

**Disclosures** None.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Heiberg T, Kvien TK (2002) Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum 47(4):391–397. https://doi.org/10.1002/art.10515
2. Lee YC, Bingham CO 3rd, Edwards RR, Marder W, Phillips K, Bolster MB, Clauw DJ, Moreland LW, Lu B, Wohlfahrt A, Zhang Z, Neogi T (2018) Association between pain sensitization and disease activity in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Care Res 70(2):197–204. https://doi.org/10.1002acr.23266
3. Lee YC, Cui J, Lu B, Frits ML, Iannaccone CK, Shadick NA, Weinblatt ME, Solomon DH (2011) Pain persists in DAS28 rheumatoid arthritis remission but not in ACR/EULAR remission: a longitudinal observational study. Arthritis Res Ther 13(3):R83. https://doi.org/10.1186/ar3353
4. Fraenkel L, Batson JM, England BR, St Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK, Kerr G, Kremer J, Nakamura MC, Russell LA, Singh JA, Smith BJ, Sparks JA, Venkatachalam S, Weinblatt ME, Ali-Gibbawi M, Baker JK, Barbour KE, Barton JL, Cappelli L, Chamseddine F, George M, Johnson SR, Kahale L, Karam BS, Khamis AM, Navarro-Millán I, Mirza R, Schwab P, Singh N, Turgunbaev M, Turner AS, Yaacoub S, Akl EA (2021) 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res 73(7):924–939. https://doi.org/10.1002acr.24596
5. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McNees JB, Sepriano A, van Volkenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumashes M, Li Z, Mariette X, Müller-Ladner U, Myser ES, da Silva JAP, Poór G, Pope JE, Rubbert-Roth A, Ruysen-Weitrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, Westhovens R, van der Heijde D (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685–699. https://doi.org/10.1136/annrheumdis-2019-216655
6. Sánchez-Flórez JC, Seija-Butnaru D, Valero EG, Acosta C, Amaya S (2021) Pain management strategies in rheumatoid arthritis: a narrative review. J Pain Palliat Care Pharmacother 35(4):291–299. https://doi.org/10.1080/15360288.2021.1973647
7. Ahmed S, Magan T, Vargas M, Harrison A, Sofat N (2014) Use of the painDETECT tool in rheumatoid arthritis suggests neuropathic and sensitization components in pain reporting. J Pain 7:579–588. https://doi.org/10.2147/jpr.s69011
8. Mucke M, Cuhls H, Radbruch L, Baron R, Maier C, Tolle T, Treede RD, Rolke R (2014) Quantitative sensory testing. Schmerz (Berlin, Germany) 28(6):635–646; quiz 647–638. https://doi.org/10.1007/s00482-014-1485-4
9. Rolke R, Magerl W, Campbell KA, Schalber C, Caspari S, Birklein F, Treede RD (2006) Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain (London, England) 10(1):77–88. https://doi.org/10.1016/j.ejpain.2005.02.003
10. Cruz-Almeida Y, Fillingim RB (2014) Can quantitative sensory testing move us closer to mechanism-based pain management? Pain Med (Malden, Mass) 15(1):61–72. https://doi.org/10.1111/pme.12230
11. Heisler AC, Song J, Dunlop DD, Wohlfahrt A, Bingham CO 3rd, Bolster MB, Clauw DJ, Marder W, Phillips K, Neogi T, Lee YC (2019) Association of pain centralization and patient-reported pain in active rheumatoid arthritis. Arthritis Care Res. https://doi.org/10.1002acr.23994
12. Granovsky Y, Anand P, Nakae A, Nascimento O, Smith B, Sprecher E, Valls-Sole J (2016) Normative data for Adelta contact heat evoked potentials in adult population: a multicenter study. Pain 157(5):1156–1163. https://doi.org/10.1097/j.pain.0000000000000495
13. Seifert CL, Nitsche D, Valet M, Tolle TR, Sprenger T (2008) Contact heat evoked potentials for the evaluation of pain pathways. Der Nervenarzt 79 (8):899, 902–897. https://doi.org/10.1007/s00115-008-2465-7
14. Mouraux A, Iannetti GD (2018) The search for pain biomarkers in the human brain. Brain J Neurol 141(12):3290–3307. https://doi.org/10.1093/brain/awy281
15. Iannetti GD, Hughes NP, Lee MC, Mouraux A (2008) Determinants of laser-evoked EEG responses: pain perception or stimulus salience? J Neurophysiol 100(2):815–828. https://doi.org/10.1152/jn.00097.2008
16. Malver LP, Brokjer A, Staalh C, Graversen C, Andresen T, Drewes AM (2014) Electroencephalography and analgesics. Br J Clin Pharmacol 77(1):72–95. https://doi.org/10.1111/bcp.12137
17. Rifbjerg-Madsen S, Christensen AW, Boesen M, Christensen R, Danneskiold-Samsøe B, Bliddal H, Bartels EM, Locht H, Amris K (2014) Can the painDETECT questionnaire score and MRI help predict treatment outcome in rheumatoid arthritis: protocol for
the Frederiksberg hospital’s Rheumatoid Arthritis, pain assessment and Medical Evaluation (FRAME-cohort) study. BMJ Open 4(11):e006058. https://doi.org/10.1136/bmjopen-2014-006058

18. Mucke M, Cuhls H, Radbruch L, Baron R, Maier C, Tolle T, Treede RD, Rolke R (2016) Quantitative sensory testing (QST). English version. Schmerz (Berlin, Germany). https://doi.org/10.1007/s00482-015-0093-2

19. Metting van Rijn AC, Peper A, Grimbergen CA (1990) High-quality recording of bioelectric events. Part 1 Interference reduction, theory and practice. Medical & biological engineering & computing 28(5):389–397. https://doi.org/10.1007/bf02441961

20. Delorme A, Makeig S (2004) EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysis. J Neurosci Methods 134(1):9–21. https://doi.org/10.1016/j.jneumeth.2003.10.009

21. M Anders B Anders M Kreuzer S Zinn C Walter 2020 Application of referencing techniques in EEG-based recordings of contact heat evoked potentials (CHEPS) Front Hum Neurosci 14 https://doi.org/10.3389/fnhum.2020.559969

22. Chang C-Y, Hsu S-H, Pion-Tonachini L, Jung T-P (2018) Evaluation of architecture subspace reconstruction for automatic EEG artifact removal, vol 2018. https://doi.org/10.1109/EMBC.2018.8512547

23. Blumenstiel K, Gerhardt A, Rolke R, Bieber C, Teszar J, Friederich HC, Eich W, Treede RD (2011) Quantitative sensory testing profiles in chronic back pain are distinct from those in fibromyalgia. Clin J Pain 27(8):682–690. https://doi.org/10.1097/AJP.0b013e3182177654

24. Hoo ZH, Candlish J, Teare D (2017) What is an ROC curve? Emergency Med J EMI 34(6):357–359. https://doi.org/10.1136/emermed-2017-206735

25. Hentschke H, Stutgen MC (2011) Computation of measures of effect size for neuroscience data sets. Eur J Neurosci 34(12):1887–1894. https://doi.org/10.1111/j.1460-9568.2011.07902.x

26. Cohen J (1988) Statistical power analysis for the behavioral sciences. L. Erlbaum Associates, Hillsdale, N.J.

27. Joharatnam N, McWilliams DF, Wilson D, Wheeler M, Pande I, Walsh DA (2015) A cross-sectional study of pain sensitivity, disease-activity assessment, mental health, and fibromyalgia status in rheumatoid arthritis. Arthritis Res Ther 17:11. https://doi.org/10.1186/s13075-015-0525-5

28. Edwards RR, Wasan AD, Bingham CO 3rd, Bathon J, Haythornthwaite JA, Smith MT, Page GG (2009) Enhanced reactivity to pain in patients with rheumatoid arthritis. Arthritis Res Ther 11(3):R61. https://doi.org/10.1186/ar2684

29. Terezi R, Romano E, Manetti M, Peruzzi F, Nacci F, Maturacci-Cerinic M, Guiducci S (2013) Neuropeptides activate TRPV1 in rheumatoid arthritis fibroblast-like synoviocytes and foster IL-6 and IL-8 production. Ann Rheum Dis 72(6):1107–1109. https://doi.org/10.1136/annrheumdis-2012-202846

30. Morris VH, Cruwys SC, Kidd BL (1997) Characterisation of capsaicin-induced mechanical hyperalgesia as a marker for altered nociceptive processing in patients with rheumatoid arthritis. Pain 71(2):179–186

31. Hsieh WS, Kung CC, Huang SL, Lin SC, Sun WH (2017) TDAG8, TRPV1, and ASIC3 involved in establishing hyperalgesic priming in experimental rheumatoid arthritis. Sci Rep 7(1):8870. https://doi.org/10.1038/s41598-017-09200-6

32. Carnevale V, Rohacs T (2016) TRPV1: a target for rational drug design. Pharmaceuticals (Basel, Switzerland) 9(3). https://doi.org/10.3390/ph9030052

33. Koplas PA, Rosenberg RL, Oxford GS (1997) The role of calcium in the desensitization of capsaicin responses in rat dorsal root ganglion neurons. J Neurosci Off J Soc Neurosci 17(10):3525–3537

34. Jensen TS, Finnerup NB (2014) Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol 13(9):924–935. https://doi.org/10.1016/s1474-4422(14)70102-4

35. Baron R, Maier C, Attal N, Binder A, Bouhassira D, Cruccu G, Finnerup NB, Haanpää M, Hansson P, Hüllmann P, Jensen TS, Freynhagen R, Kennedy JD, Magerl W, Mainka T, Reimer M, Rice AS, Segerdahl M, Serra J, Sundrup S, Sommer C, Tolle T, Vollert J, Treede RD (2017) Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain 158(2):261–272. https://doi.org/10.1097/j.pain.0000000000000753

36. Jara LJ, López-Zamora B, Ordoñez-González I, Galaviz-Sánchez MF, Gutierrez-Melgarjoe CI, Saavedra M, Vera-Lastra O, Cruz-Domínguez MP, Medina G (2021) The immune-neuroendocrine system in COVID-19, advanced age and rheumatic diseases. Autoimmun Rev 20(11):102946. https://doi.org/10.1016/j.autrev.2021.102946

37. Madsen CS, Johnsen B, Fuglsang-Frederiksen A, Jensen TS, Finnerup NB (2012) Increased contact heat pain and shortened latencies of contact heat evoked potentials following capsaicin-induced heat hyperalgesia. Clin Neurophysiol Off J Int Fedr Elet Clin Neurophysiol 123(7):1429–1436. https://doi.org/10.1016/j.clinph.2011.11.032

38. Chao C-C, Hsieh S-C, Tseng M-T, Chang Y-C, Hsieh S-T (2008) Patterns of contact heat evoked potentials (CHEPs) in neuropathy with skin denervation: correlation of CHEP amplitude with intraepidermal nerve fibre density. Clin Neurophysiol 119(3):653–661. https://doi.org/10.1016/j.clinph.2007.11.043

39. Atherton DD, Facer P, Roberts KM, Misra VP, Chizh BA, Boutrna C, Anand P (2007) Use of the novel contact heat evoked potential stimulator (CHEPS) for the assessment of small fibre neuropathy: correlations with skin flare responses and intra-epidermal nerve fibre counts. BMC Neurol 7(1):21

40. Wong MC, Chung JH (2011) Feasibility of contact heat evoked potentials for detection of diabetic neuropathy. Muscle Nerve 44(6):902–906. https://doi.org/10.1002/mus.22192

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.